Kala Bio tumbles after CEO resignation
12/02/2025 16:55
** Shares of drug maker Kala Bio KALA.O fall 34.6% to
$7.12, set for record single-day fall
** Company says its CEO Mark Iwicki has resigned, and
President Todd Bazemore has been appointed as interim CEO
** Iwicki has been with KALA for nearly a decade
** Iwicki will continue as chair of the board
** KALA is set to report mid-stage trial data of its drug,
KPI-012, in the second quarter of 2025, for the treatment of
persistent corneal epithelial defects, a condition where
injuries to the cornea, the clear front part of the eye, don't
heal properly
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))